<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04124406</url>
  </required_header>
  <id_info>
    <org_study_id>2019-08</org_study_id>
    <nct_id>NCT04124406</nct_id>
  </id_info>
  <brief_title>Voyage: Real-World Impact of the Multi-target Stool DNA Test on CRC Screening and Mortality</brief_title>
  <official_title>Voyage: Real-World Impact of the Multi-target Stool DNA Test on CRC Screening and Mortality</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Exact Sciences Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Exact Sciences Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to gather information about the long term health of people who
      have been prescribed the Cologuard test, which is used for colorectal cancer (CRC) screening.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participates will be consented for prospective follow-up for health outcomes, which will be
      ascertained through periodic contacts. Participants will complete a baseline health
      questionnaire survey (T0) and a 1-year follow-up questionnaire survey (T1), allow access to
      medical records, when available, and allow future contacts for additional surveys.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 18, 2019</start_date>
  <completion_date type="Anticipated">December 2029</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Enrollment of Subjects</measure>
    <time_frame>3 years</time_frame>
    <description>Enrollment of 150,000 subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnostic colonoscopy</measure>
    <time_frame>4.5 years</time_frame>
    <description>Proportion having diagnostic colonoscopy within 1 year after positive CG test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRC Frequency</measure>
    <time_frame>10 years</time_frame>
    <description>Frequency of CRC among enrollees</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Rates Comparison</measure>
    <time_frame>10 years</time_frame>
    <description>Comparison with national rates (i.e., SEER cancer registry rates) adjusted to reflect a) the age- and sex- distribution of CG users, b) that 25% of colorectal cancers occur in high risk patients, and c) the attrition rate of our longitudinal cohort</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150000</enrollment>
  <condition>Colon Cancer</condition>
  <arm_group>
    <arm_group_label>Adults Prescribed Cologuard</arm_group_label>
    <description>Adults prescribed Cologuard for routine colon cancer screening by their healthcare provider.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cologuard</intervention_name>
    <description>multi-target stool Deoxyribonucleic Acid (MT-sDNA) screening test</description>
    <arm_group_label>Adults Prescribed Cologuard</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults prescribed Cologuard for routine colon cancer screening by their healthcare
        provider.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Resident of the United States

          -  Age 18 years or older

          -  Able to provide informed consent

          -  Able to complete surveys in English or Spanish

          -  Valid order for Cologuard screening

        Exclusion Criteria:

          -  N/A
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexandra Massoud</last_name>
    <phone>608-957-5652</phone>
    <email>amassoud@exactsciences.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet E. Olson, Ph.D</last_name>
      <phone>833-242-4428</phone>
      <email>VOYAGESTUDY@mayo.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 10, 2019</study_first_submitted>
  <study_first_submitted_qc>October 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2019</study_first_posted>
  <last_update_submitted>January 17, 2020</last_update_submitted>
  <last_update_submitted_qc>January 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in publications of the study will be shared after de-identification. This may include text, tables, figures, and appendices. The study protocol (including statistical methods), informed consent form, and clinical study report will also be shared. Data will be shared with researchers who provide a methodologically sound proposal to achieve the aims outlined in the approved proposal.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data will be available from 2 years and ending 4 years after publication.</ipd_time_frame>
    <ipd_access_criteria>Proposals for access to data should be directed to clinicaltrials@exactsciences.com. To gain access, data requestors will need to provide a methodologically sound proposal and sign a data access agreement. Researchers are required to obtain necessary IRB/EC approvals or waivers as applicable to conduct research.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

